Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (NCT03395197), a randomized phase 3 study. The primary outcome is Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1.

2. Clinical Question

The clinical question therefore has an efficacy component and a safety component in the record. The stated study objective concerns rPFS among men with mCRPC receiving the combination versus enzalutamide after confirmation of the starting talazoparib dose. The detailed primary outcome information concerns early TEAEs in Part 1, rather than an rPFS comparison. The record does not provide an rPFS estimate in the registry record, so the treatment comparison cannot be characterized by an efficacy effect or its precision. The Part 2 adverse-event counts describe additional safety groups, including all-comer groups and groups identified as having DDR deficiencies.

3. Trial Design

This was a phase 3, randomized, double-blind, placebo-controlled, parallel-group study. The registry lists quadruple masking; it does not identify which specific parties were masked. Enrollment was 1054. The study start date was 2017-12-18, and the primary completion date was 2022-10-03. The registry status is active, not recruiting.

The study compared talazoparib with enzalutamide against placebo with enzalutamide. The arm descriptions call these the combination and monotherapy arms, respectively. The brief summary says that the comparison of rPFS was made after confirmation of the starting dose of talazoparib in combination with enzalutamide. The listed Part 1 groups include talazoparib 1 mg QD with enzalutamide and talazoparib 0.5 mg QD with enzalutamide. Part 2 includes all-comer groups receiving talazoparib plus enzalutamide or placebo plus enzalutamide, as well as groups described as participants with DDR deficiencies.

Randomization is intended, in general, to support comparable groups at the start of a trial. Blinding can reduce the influence of treatment knowledge on participant care, reporting, and assessment. Those design features do not by themselves establish that the groups were comparable in every respect or resolve limitations in how outcomes were recorded. The registry record does not specify the exact randomization procedure, allocation ratio, or the parties covered by quadruple masking. It also does not report the protocol details for how the Part 1 dose confirmation informed Part 2.

The registry lists 8 outcome measures and 2 analyses. Those counts do not explain the analysis methods or identify which estimates were prespecified. The detailed primary outcome is a count of participants with TEAEs in Part 1 during the stated early dosing period; it is not the rPFS outcome named in the brief summary.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: As of 16 Aug 2022, 19 participants were enrolled in Part 1, 805 participants with metastatic castrate-resistant prostate cancer (mCRPC) unselected for DNA damage response (DDR) deficiencies were randomized in Part 2 Cohort 1. As of 03 Oct 2022, 169 DDR-deficient participants enrolled in Cohort 1 were combined with the 230 DDR-deficient participants enrolled in Cohort 2 such that 399 participants were included in the analysis for participants with DDR deficiencies.

Study Recruitment

Analysis for Part 1 and Part 2 Cohort 1

Reasons for not completing this period:

Analysis for DDR-Deficient Participants

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Included all participants in Part 1 who received at least 1 dose of study intervention (talazoparib or enzalutamide).

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Included all participants who received at least 1 dose of study treatment (talazoparib or enzalutamide) in Part 1, and all participants who were randomized to double-blind study treatment in Part 2 regardless of whether or not treatment was administered.

Only the first 6 of 7 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1, measured over Post dose on Day 1 up to Day 66 in Part 1.

The detailed primary outcome counts participants with treatment-emergent adverse events occurring within the first 66 days of dosing in Part 1. Its timeframe is post dose on Day 1 up to Day 66. The outcome population includes all Part 1 participants who received at least 1 dose of study intervention, whether talazoparib or enzalutamide. A TEAE is defined as an adverse event that newly occurs or worsens after the first dose.

An adverse event is an untoward medical occurrence in a participant who received study intervention, regardless of whether a causal relationship to the intervention is considered possible. The registry distinguishes serious TEAEs using outcomes such as death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability or incapacity, or congenital anomaly. Seriousness was assessed according to the investigator's assessment. The outcome description also gives CTCAE version 4 severity grades, ranging from Grade 1, mild, through Grade 5, death related to an AE.

Counting participants with an event is a binary-outcome approach: each participant is classified according to whether the event occurred, rather than by the number of separate event episodes. Such outcomes can help describe how many participants experienced an event during a defined observation period. The short, specific Part 1 timeframe does not describe later safety experience or establish whether an event was caused by treatment. The registry also describes rPFS as the study's comparison in its brief summary, but an rPFS definition and result are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a count of participants with an event tell us?

A binary outcome records whether each participant experienced an event during the defined period. For this primary outcome, the event is a TEAE and the period is post dose on Day 1 up to Day 66 in Part 1. The count of affected participants is meaningful alongside the number at risk, because the count alone does not indicate the size of the group observed. The registry presents these counts by group but does not provide a comparative effect estimate for the primary outcome.

In a comparative analysis of a binary outcome, investigators may report quantities such as a risk difference, risk ratio, or odds ratio. These express different aspects of the contrast between groups, and their interpretation depends on the analysis and outcome definition. No such estimate for the detailed primary outcome is reported in the registry record. No confidence interval is reported for these comparisons either. In general, a confidence interval communicates the range of values reasonably compatible with the data and analysis; it helps readers judge precision as well as the direction of an estimate. A count without an interval cannot convey that uncertainty by itself.

Why distinguish serious from other adverse events?

Seriousness classifies an adverse event according to its consequences or significance, while severity grades describe the intensity of an event. The registry's definition of serious events includes outcomes such as hospitalization, a life-threatening experience, or death, and says seriousness was determined according to the investigator's assessment. The CTCAE version 4 description assigns grades from mild to death related to an AE. These classifications are not interchangeable: a serious event is not necessarily the most severe event, and an event's grade does not establish that treatment caused it.

The group listings separately report participants at risk and participants affected for serious and other events. These summaries are useful for describing the recorded safety experience, but they do not give event onset, duration, recurrence, or severity distribution. A participant count also does not reveal how many event episodes occurred. The registry record does not describe how missing safety information was handled or whether exposure duration differed between groups.

What can randomization and masking contribute?

As a general statistical principle, random allocation can reduce systematic differences between groups at baseline, especially when a study is conducted and analyzed as planned. It does not guarantee identical groups, particularly for characteristics that are uncommon. Masking can reduce some forms of bias in reporting, clinical management, and outcome assessment. The registry labels the study randomized and quadruple masked, but the parties covered by masking and the allocation procedure are not reported in the registry record. Those labels alone do not establish that masking was maintained throughout the study.

The parallel-group design means participants are assigned to a study arm rather than being described as crossing from one treatment to another. The record names the combination and placebo-plus-enzalutamide arms and lists distinct Part 1 and Part 2 groups. The precise transition between parts, and how dose confirmation affected later treatment assignments or analyses, is not reported in the registry record.

What is the role of the planning illustration?

In general, sample-size planning estimates how many participants or events may be needed to detect a chosen effect under specified assumptions. The registry's planning-illustration description says it uses a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect set as a stated fraction of the observed effect. It also distinguishes planning participants per arm from total events for time-to-event outcomes. Such values are planning illustrations, not observed power and not a description of the trial's own design justification. The trial's sample-size justification is not reported in the registry record.

A significance level is a threshold used in a testing procedure; it does not state the probability that a treatment effect is true. A normal approximation is a mathematical simplification that may be useful for planning under appropriate conditions. For count data with greater variability than a basic model assumes, over-dispersion can make conventional uncertainty estimates too narrow; a suitable analysis may need to account for that extra variation. This is a general consideration, not a claim that over-dispersion occurred in this trial. The registry record does not identify an over-dispersion model for the listed adverse-event counts.

The registry lists 2 analyses but does not describe their statistical procedures. The primary outcome contains several categories or time points and is not reduced to a single comparison in the posted analysis. Without a reported model, adjustment strategy, or treatment-effect estimate, it is not possible to assess the analysis's handling of covariates or quantify the precision of a contrast. Nor can the number of analyses alone establish which results were primary, confirmatory, or exploratory.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 8 outcome measures and 2 analyses, but the multiplicity strategy is not reported in the registry record. Multiplicity arises when several outcomes, time points, subgroups, or comparisons are examined. In general, repeated testing can increase the chance of finding an apparently notable result by chance unless the testing plan accounts for the number and relationship of those tests. The available record does not say whether any adjustment was planned, which outcome was designated for formal hypothesis testing, or how the rPFS comparison relates to the detailed TEAE outcome.

The primary outcome population is specified as all Part 1 participants who received at least 1 dose of study intervention. This is a treated safety population definition, not necessarily the population used for an efficacy analysis. The registry does not report the analysis population for rPFS or other outcomes, nor whether participants were analyzed according to randomized assignment, treatment received, or another rule. It also does not report how participants who discontinued, had incomplete follow-up, or lacked outcome assessments were handled.

Missing-data methods, censoring rules for rPFS, and procedures for handling events after treatment discontinuation are not reported in the registry record. These details matter because incomplete observation can affect both the number of participants classified with an event and time-to-event estimates. The record's counts should therefore be read as posted descriptive results, not as evidence that missingness or follow-up differences had no effect.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: anaemia (16.7%), cholecystitis (16.7%), hyperglycaemia (16.7%), pulmonary embolism (16.7%), aortic thrombosis (16.7%).

The serious adverse-event figures are participant counts, with the number at risk stated for each group. For example, in the Part 2 all-comer groups, 157 of 398 participants in the talazoparib-plus-enzalutamide group and 107 of 401 in the placebo-plus-enzalutamide group are listed as affected by serious events. The corresponding DDR-deficiency groups list 60 of 198 and 40 of 199 participants affected. These are descriptive group summaries; they do not include an adjusted comparison or a measure of uncertainty.

The figures for other adverse events are also counts of participants affected, not counts of event episodes. The registry lists 377 of 398 and 351 of 401 in the Part 2 all-comer groups, and 190 of 198 and 182 of 199 in the DDR-deficiency groups. These categories should not be assumed to be mutually exclusive with serious events unless the registry states that they are; the record does not clarify that point in the information.

The death counts are listed separately: 123 and 129 in the Part 2 all-comer groups, and 43 and 53 in the DDR-deficiency groups. The counts do not establish that deaths were caused by treatment or were classified as adverse-event-related deaths. The selected serious-event percentages also lack a reported denominator. Seriousness, event frequency, causal attribution, and treatment effect are distinct concepts, and the posted figures do not resolve all of them.

12. What the Result Does, and Does Not, Mean

The record describes a randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide compared with placebo with enzalutamide in mCRPC. It also reports adverse-event counts across Part 1 dose groups and Part 2 all-comer and DDR-deficiency groups. These data can be read as a description of participants recorded as affected within the listed groupings. They do not, on their own, establish the size, direction, or precision of a causal treatment effect.

The brief study summary identifies rPFS as the comparison of interest. However, the detailed primary outcome described in the record is early TEAEs in Part 1, and no rPFS result is reported in the registry record. It is therefore not possible to draw a statistical conclusion about the rPFS comparison from these adverse-event counts. Similarly, the TEAE counts do not show whether the observed differences between groups are compatible with chance or reflect a systematic treatment effect, because comparative estimates and uncertainty measures are not reported.

The record's definitions help clarify what is counted. TEAEs are newly occurring or worsening adverse events after the first dose, while serious events are classified by specified consequences or significance. Neither classification, on its own, determines causality. The listed death counts should not be treated as treatment-attributed deaths, and the selected percentages for serious-event terms cannot be interpreted as population rates without a stated denominator.

In general, trial design and outcome data answer different questions: randomization and masking describe how a comparison was organized, while estimates and uncertainty from a prespecified analysis describe what the observed data support. The registry provides design labels, enrollment, outcome definitions, and descriptive counts, but the statistical analysis plan, missing-data handling, multiplicity approach, and relevant inferential estimates are not reported in the registry record. The safest statistical reading is consequently limited to the descriptions and counts themselves.

13. Why This Trial Matters Statistically

This trial is statistically notable in the way its registry record separates a broad efficacy objective from a detailed safety outcome. The brief summary names rPFS as the comparison of interest, while the primary outcome measure described in detail counts TEAEs within the first 66 days of dosing in Part 1. Keeping those endpoints distinct prevents an early safety count from being mistaken for an efficacy result.

The record also distinguishes a dose-confirmation part from Part 2 groups, including all-comer and DDR-deficiency groups. That structure matters when interpreting counts: the Part 1 groups are small dose groups, whereas the Part 2 listings contain the larger treatment groups and separately identified subgroup results. Results from one part or population should not automatically be generalized to another. The record does not describe the full analysis plan linking the parts, so that relationship cannot be evaluated in detail.

For biostatistical interpretation, the availability of group counts without comparative estimates highlights the difference between descriptive evidence and inferential evidence. Counts tell readers how many participants were recorded as affected, but they do not quantify the uncertainty around a treatment contrast or show how covariates, follow-up, and missing observations were handled. A study's randomized, masked design is important context, but it does not replace transparent reporting of estimands, analysis populations, methods, and precision.

The record therefore offers useful information about design and the organization of safety reporting while leaving major inferential questions unresolved. That distinction is valuable for clinical researchers: a registry entry can document study structure and outcome definitions, yet still lack the details needed to assess a specific treatment-effect estimate.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record describes a primary outcome focused on TEAEs during the first 66 days of Part 1 dosing, while its brief summary describes an rPFS comparison. The connection between these two descriptions is not explained. No rPFS result, treatment-effect estimate, confidence interval, or p-value is reported in the registry record. The posted safety counts therefore cannot answer the efficacy question named in the brief summary.

The Part 1 groups are limited in size, with 13 participants at risk in the 1 mg QD group and 6 in the 0.5 mg QD group for the listed safety outcomes. Sparse group counts can be highly sensitive to a small number of participants, and no uncertainty estimates are reported for them. The record also provides no exposure-adjusted summaries, follow-up distribution, or details on event recurrence, onset, duration, or severity by group.

For the selected serious-event terms, the denominator behind the listed percentages is not reported in the registry record. The relationship between serious and other event categories is also not clarified in the information. Death counts are listed, but their causes and relationship to treatment are not specified. The counts should not be interpreted as evidence of attribution.

The registry does not report the randomization procedure, allocation ratio, exact parties covered by masking, analysis populations for efficacy outcomes, missing-data methods, censoring rules, multiplicity plan, or statistical models used for the reported analyses. The sample-size justification is not reported in the registry record. These omissions limit evaluation of bias, precision, and the reproducibility of the analysis. The registry status and listed completion date provide study-record context, but they do not supply the missing statistical details.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — NCT03395197.
• Registry record last updated 2026-11-05; status last verified 2026-11.
• Results first posted 2024-01-17.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a phase 3, randomized, double-blind, placebo-controlled, parallel-group study of talazoparib plus enzalutamide versus placebo plus enzalutamide in mCRPC. Enrollment was 1054; the study started on 2017-12-18, had a primary completion date of 2022-10-03, and is listed as active, not recruiting. Quadruple masking is recorded, but the masked parties are not specified.

The brief summary identifies rPFS as the study comparison. The detailed primary outcome counts participants with TEAEs in Part 1 from post dose on Day 1 up to Day 66. Safety counts are also listed for Part 2 all-comer and DDR-deficiency groups. The registry lists 8 outcome measures and 2 analyses, but does not report the statistical analysis plan, multiplicity approach, missing-data methods, or inferential estimates needed to assess treatment effects.